4027-56-9

Usage

Uses

Used in Pharmaceutical Industry:
5-methyl-1H-pyrazole-3-carboxamide is used as a building block for the synthesis of various pharmaceuticals due to its versatile reactivity. It contributes to the development of new drugs with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical industry, 5-methyl-1H-pyrazole-3-carboxamide is utilized as a key component in the production of agrochemicals. Its reactivity allows for the creation of compounds with pesticidal properties, enhancing crop protection and yield.
Used in Coordination Chemistry:
5-methyl-1H-pyrazole-3-carboxamide is employed as a ligand in coordination chemistry. It forms complexes with metal ions, which can be used in various applications, such as catalysis and the development of new materials with unique properties.
Used in Antiviral Applications:
5-methyl-1H-pyrazole-3-carboxamide has been evaluated for its antiviral activities. It shows potential as an antiviral agent, offering a new avenue for the development of treatments against viral infections.
Used in Anticancer Applications:
In the field of medicinal chemistry, 5-methyl-1H-pyrazole-3-carboxamide has been studied for its anticancer properties. It may contribute to the development of new cancer therapies, providing an additional tool in the fight against cancer.

Upstream product

• 402-61-9 5-methyl-1H-pyrazole-3-carboxylic acid 
• 49664-33-7 2,7-dimethyl-4H,9H-dipyrazolo<1,5-a,1',5'-d>pyrazine-4,9-dione 
• 4027-57-0 ethyl 5-methyl-1H-pyrazole-3-carboxylate 

Downstream Products

• 38693-82-2 5-methyl-1H-pyrazole-3-carbonitrile 
• 32258-58-5 4-bromo-5-methyl-1H-pyrazole-3-carboxamide 
• 1780-72-9 4-bromo-5-methyl-1H-pyrazol-3-amine 

Relevant academic research and scientific papers

In Silico Evaluation of the Binding Site of Fucosyltransferase 8 and First Attempts to Synthesize an Inhibitor with Drug-Like Properties

Core fucosylation of N-glycans is catalyzed by fucosyltransferase 8 and is associated with various types of cancer. Most reported fucosyltransferase inhibitors contain non-drug-like features, such as charged groups. New starting points for the development of inhibitors of fucosyltransferase 8 using a fragment-based strategy are presented. Firstly, we discuss the potential of a new putative binding site of fucosyltransferase 8 that, according to a molecular dynamics (MD) simulation, is made accessible by a significant motion of the SH3 domain. This might enable the design of completely new inhibitor types for fucosyltransferase 8. Secondly, we have performed a docking study targeting the donor binding site of fucosyltransferase 8, and this yielded two fragments that were linked and trimmed in silico. The resulting ligand was synthesized. Saturation transfer difference (STD) NMR confirmed binding of the ligand featuring a pyrazole core that mimics the guanine moiety. This ligand represents the first low-molecular-weight compound for the development of inhibitors of fucosyltransferase 8 with drug-like properties.

Fluorinated pyrazole acids are agonists of the high affinity niacin receptor GPR109a

A series of 5-alkyl pyrazole-3-carboxylic acids were prepared and found to act as potent and selective agonists of the human GPCR, GPR109a, the high affinity nicotinic acid receptor. No activity was observed at the highly homologous low affinity niacin receptor, GPR109b. A further series of 4-fluoro-5-alkyl pyrazole-3-carboxylic acids were shown to display similar potency. One example from the series was shown to have improved properties in vivo compared to niacin.